


The aim of the fund is to achieve long term growth from investments principally in European equities, excluding the UK.
| Name | % Net Assets |
|---|---|
| Roche | 4.0% |
| Novartis | 3.7% |
| BNP Paribas | 3.1% |
| Novo-Nordisk | 3.0% |
| Telefónica | 2.6% |
| Allianz SE | 2.6% |
| Nordea Bank | 2.5% |
| SAP | 2.4% |
| Ericsson | 2.4% |
| Banco Bilbao Vizcaya Argentaria | 2.3% |
| Key | % Net Assets |
|---|---|
| 4.0% | |
| 3.7% | |
| 3.1% | |
| 3.0% | |
| 86.2% |
| Date | 10-Jan-2025 |
|---|---|
| NAV | 141.46p |
| Currency | GBP |
| Change | -0.100p |
| % | -0.07% |
| YTD change | 1.97p |
| YTD % | 1.41% |
| Fund Inception | 28/10/2011 |
|---|---|
| Fund Manager | Mark Page / Laurent Millet |
| TER | - |
| Minimum Investment | |
|---|---|
| Initial | £250000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | 1.00% |
| Annual Mang't | 0.75% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research